Live from ASCO 2023 | Updated Data of Olverembatinib in SDH-Deficient GIST including a CBR of 93.8% Signals a Potential Clinical Breakthrough
SUZHOU, China and ROCKVILLE, Md., June 5, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated clinical results of olverembatinib (HQP1351), a third-generation tyrosine kinase inhibitor (TKI), in patients with TKI-resistant...
ISCT 2023: Late-breaking SCG101 Data Show 100% HBsAg+ Hepatocyte Eradication and 74.5% HCC Tumour Reduction With Single Dose HBsAg-specific TCR-T Cell Therapy
SINGAPORE, June 5, 2023 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, presented late-breaking data from its first-in-class autologous HBsAg-specific T-Cell receptor-engineered T Cell (TCR-T) Therapy – SCG101 – at the International Society for Cell & Gene Therapy (ISCT) conference in Paris, France. SCG101 showed significant antitumor...
Harbour BioMed Announces First Patient Dosed in Phase I Study of First-in-Class Anti-B7H7 (HHLA2) Antibody HBM1020
HBM1020 is a first-in-class therapeutic monoclonal antibody against B7H7/HHLA2 entering clinical development globally. HBM1020 was generated from Harbour Mice® H2L2 transgenic mice platform. HBM1020 has great potential to address huge unmet medical needs in patients with advanced malignancies. CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 5, 2023 /PRNewswire/ -- Harbour BioMed (HKEX: 02142) announced that the...
LOTTE BIOLOGICS to Kick off their CDMO Business Campaign at ‘BIO International Convention 2023’
Exclusive booth and private meeting rooms to be utilized for robust business initiatives SEOUL, South Korea, June 5, 2023 /PRNewswire/ -- LOTTE BIOLOGICS, under the leadership of CEO Richard Lee, enthusiastically disclosed its participation in the upcoming 'BIO International Convention 2023' to be held from June 5th to June 8th, 2023, at the illustrious Boston Convention &...
VVN539 met primary study endpoints in US phase IIa clinical study for the treatment of glaucoma
SHANGHAI, June 5, 2023 /PRNewswire/ -- This was a Phase 2, double-masked, randomized, vehicle-controlled, dose-response study to assess the safety and ocular hypotensive efficacy of VVN539 in subjects with primary open angle glaucoma (POAG) or ocular hypertension (OHT). The primary objective was to evaluate the ocular hypotensive efficacy of 2 concentrations of VVN539 Ophthalmic Solution (0.04% and 0.02%) in patients...
Innovent Presents Phase 1b Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2023 ASCO Annual Meeting
ROCKVILLE, Md. and SUZHOU, China, June 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announced that Phase 1b clinical data of IBI110 (anti-LAG-3 monoclonal antibody) in the first-line treatment of gastric cancer and first-line...
Innovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting
ROCKVILLE, Md. and SUZHOU, China, June 4, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, updated the Phase 1b efficacy and safety results of IBI939 (anti-TIGIT antibody) combined with sintilimab (anti-PD-1 antibody) in previously untreated...
Gracell Biotechnologies Presents Updated Data of Deep and Durable Responses for FasTCAR-T GC012F in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting
Data on BCMA/CD19 dual-targeting FasTCAR-T GC012F showed 100% minimal residual disease (MRD) negativity and 82.8% MRD negative stringent complete response (sCR) in a predominantly high-risk relapsed/refractory multiple myeloma (RRMM) population Data on GC012F for treatment of B-NHL will be presented on June 5 in a poster presentation at 2023 ASCO Annual...
Sanyou launches new European offices and continues to promote global business landscape
SHANGHAI, June 3, 2023 /PRNewswire/ -- In May 2023, following the CIC Boston branch in US, Sanyou opens new offices in The Shard London and CIC Rotterdam respectively, to rapidly promote the globalization of business landscape. Headquartered in Shanghai China, Sanyou Biopharmaceuticals Co., Ltd. is a world-leading national high-tech biotechnology enterprise focusing on R&D and services of innovative biological drugs....
Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST
ROCKVILLE, Md. and SUZHOU, China, June 3, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD)...
